American Society of Clinical Oncology

Oncology & Cancer

Olaparib slows growth of BRCA-related metastatic breast cancer

Findings from a phase III clinical trial of about 300 women may introduce PARP inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced ...

page 3 from 7